Drug Trial Radar · NCT06433999
A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
Last checked: Nov 19, 2026Latest source record: May 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5
Actual
Start
Aug 28, 2024
Primary completion
Feb 28, 2025
Study completion Feb 28, 2025
Sponsor
- Lead sponsor
- Priovant Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, 12-week, open-label, single-arm study. The study population comprises individuals with refractory skin disease characteristic of dermatomyositis with no to minimal muscle involvement. After an up to 8-week Screening Period, eligible participants will receive brepocitinib 30 mg orally (PO) QD for 12 weeks.
Conditions
- Dermatomyositis
- Dermatomyositis, Adult Type
Interventions
BrepocitinibDrug
Oral Brepocitinib PO QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint is the change in CDASI-A score from baseline through Week 12Time frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Scottsdale, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.